Suggested remit: To appraise the clinical and cost effectiveness of lenvatinib with pembrolizumab within its marketing authorisation for treating previously treated advanced, metastatic or recurrent endometrial cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA 2018
ID number 3811

Provisional Schedule

Committee meeting: 1 09 August 2022
Expected publication 04 January 2023

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Stakeholders

Companies sponsors Merck Sharpe Dohme
Others Department of Health and Social Care
  Welsh Government
Patient carer groups Peaches Womb Cancer Trust
Professional groups Association of Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists (RCR)
Comparator companies Eisai
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health and Social Services, Public Safety Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicine Consortium
  Welsh Health Specialised Services Committee
  Welsh Health Specialised Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
01 February 2022 Due to ERG capacity constraints, we are rescheduling the timeline for the appraisal of Pembrolizumab with lenvatinib for previously treated advanced, metastatic or recurrent endometrial cancer following the receipt of submissions in mid-February 2022. We will continue to assess the ERG capacity, and if an earlier slot becomes available, we will look to bring this topic forwards. We anticipate that the appraisal will restart in mid-March 2022 when the submissions are sent over to the Evidence Review Group (ERG) and will be discussed at committee in early October 2022.
30 November 2021 Invitation to participate
26 November 2021 Following recent discussions with the company for the appraisal of Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811], please be advised that this topic will now be appraised as a Single Technology Appraisal and not a Multiple Technology Appraisal as previously advised. For information, the appraisal is now anticipated to begin during late November 2021; with an anticipated evidence submission deadline to NICE of mid- February 2022.
18 June 2021 Following recent discussions with the company for the appraisal of Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811], please be advised that this topic will now be appraised as a Multiple Technology Appraisal. For information, the appraisal is now anticipated to begin during late October 2021; with an anticipated evidence submission deadline to NICE of mid- February 2022.
16 November 2020 - 14 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 March 2019 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual